Navelbine and the anthrapyrazoles.
This article reviews the preclinical and early clinical development of navelbine and the anthrapyrazoles. The differences in structure from the "parent" compounds that may confer clinical advantages are discussed. The preclinical data, clinical pharmacology, and Phase I trials are reviewed. Further development of these drugs in Phase II trials and comparative studies is also discussed.
Jones
A L
AL
Department of Clinical Oncology, Royal Free Hospital, London, England.
Smith
I E
IE
D000880:Anthraquinones / Q000494:pharmacology* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D011720:Pyrazoles / Q000494:pharmacology* / Q000627:therapeutic use; D014747:Vinblastine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D000077235:Vinorelbine
D000880:Anthraquinones; D000970:Antineoplastic Agents; D011720:Pyrazoles; D014747:Vinblastine; D000077235:Vinorelbine